Therefore, the use of new-targeted treatments in FXS has the potential to reverse or alleviate the obesity in affected individuals as it does in the FMR1 knockout (KO) mouse. The gene discussed is FMR1; the disease is obesity due to melanocortin 4 receptor deficiency.